TG THERAPEUTICS INC
TGTX · NASDAQ
Updated at 2026-10-14 11:07:53
- Today's High
- $55.39
- Today’s Low
- $53.63
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $55.38
- Previous Close
- $55.27
- Volume
- 758.15K
- Market Cap
- $8.46B
- P/E Ratio
- 19.19X
- EPS
- $2.74
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 3020 CARRINGTON MILL BLVD., MORRISVILLE, NC, UNITED STATES, 27560
- Country
- US
- Listing Date
- 1995-12-14
- Fiscal Year End
- December
- Shares Outstanding
- 153.08M
- CIK
- 0001001316
- Website
- www.tgtherapeutics.com
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Financial Metrics
Revenue
2026-06-30
$240.33M
2026-03-31
$204.91M
2025-12-31
$192.57M
2025-09-30
$161.7M
Operating Expenses
2026-06-30
$177.46M
2026-03-31
$136.61M
2025-12-31
$103.93M
2025-09-30
$104.18M
Net Income
2026-06-30
$7.78M
2026-03-31
$19.77M
2025-12-31
$23.03M
2025-09-30
$390.89M
Net Profit Margin
2026-06-30
3.23%
2026-03-31
9.65%
2025-12-31
11.96%
2025-09-30
241.72%
Earnings Per Share
2026-06-30
$0.05
2026-03-31
$0.18
2025-12-31
$0.14
2025-09-30
$0.16
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
$21.77M
2026-03-31
$28.1M
2025-12-31
$51.69M
2025-09-30
$32.69M
Effective Tax Rate
2026-06-30
23.96%
2026-03-31
2.87%
2025-12-31
48.91%
2025-09-30
-1.4K%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $240.33M | $204.91M | $192.57M | $161.7M |
| Operating Expenses | $177.46M | $136.61M | $103.93M | $104.18M |
| Net Income | $7.78M | $19.77M | $23.03M | $390.89M |
| Net Profit Margin | 3.23% | 9.65% | 11.96% | 241.72% |
| Earnings Per Share | $0.05 | $0.18 | $0.14 | $0.16 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | $21.77M | $28.1M | $51.69M | $32.69M |
| Effective Tax Rate | 23.96% | 2.87% | 48.91% | -1.4K% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.